Syndax Pharmaceuticals SNDX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $130.89M-3.0% | $134.93M+15.5% | $116.81M+7.5% | $108.64M-29.5% | $153.99M-0.1% | ||
| $221.17M-14.7% | $259.14M-18.8% | $319.17M-7.9% | $346.6M-3.2% | $358.2M-14.5% | ||
| $102K0.0% | $102K-53.0% | $217K0.0% | $217K0.0% | $217K0.0% | ||
| $120.97M+22.7% | $98.58M+44.6% | $68.18M+59.4% | $42.78M+83.4% | $23.32M+207% | ||
| $110.4M+37.8% | $80.11M+67.9% | $47.73M+110% | $22.73M+352% | $5.03M+1,274% | ||
| $16.1M+19.3% | $13.5M+41.8% | $9.52M-3.6% | $9.88M+16.7% | $8.46M-0.9% | ||
| $471.18M-10.8% | $528.08M-0.3% | $529.83M-0.3% | $531.68M-3.1% | $548.75M-9.0% | ||
| $177K-2.2% | $181K+41.4% | $128K— | $0— | $0— | ||
| $1.21M-9.7% | $1.34M-8.8% | $1.47M-9.7% | $1.63M-9.6% | $1.8M-10.9% | ||
| $472.67M-10.8% | $529.71M-4.0% | $551.79M-7.4% | $596.15M-7.0% | $640.71M-11.6% | ||
| $10.84M-34.6% | $16.58M+19.9% | $13.83M-20.3% | $17.35M+72.7% | $10.05M-13.6% | ||
| $74.84M-27.4% | $103.06M+33.7% | $77.11M+8.5% | $71.07M+26.9% | $55.98M-6.8% | ||
| $350M0.0% | $350M+7.0% | $327.08M— | —— | —— | ||
| $487K+3.6% | $470K+42.9% | $329K-4.4% | $344K-8.8% | $377K-20.0% | ||
| $86.17M-28.3% | $120.12M+5.2% | $114.19M+1.1% | $112.99M+19.5% | $94.55M-8.7% | ||
| $344.87M0.0% | $344.96M+7.1% | $322.18M-1.1% | $325.74M-1.6% | $331.1M-0.6% | ||
| $431.05M-7.3% | $465.08M+6.6% | $436.36M-0.5% | $438.73M+3.1% | $425.65M-2.5% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | ||
| $1.59B+1.3% | $1.57B+1.1% | $1.55B+1.2% | $1.53B+1.0% | $1.52B+0.8% | ||
| -$1.55B-2.8% | -$1.51B-4.7% | -$1.44B-4.4% | -$1.38B-5.5% | -$1.31B-6.9% | ||
| $11K-97.6% | $452K-13.9% | $525K+84.2% | $285K-45.9% | $527K+223% | ||
| $41.62M-35.6% | $64.63M-44.0% | $115.43M-26.7% | $157.42M-26.8% | $215.06M-25.4% | ||
| $472.67M-10.8% | $529.71M-4.0% | $551.79M-7.4% | $596.15M-7.0% | $640.71M-11.6% | ||
| $20.51M— | —— | —— | —— | —— | ||
| $9.18M-53.2% | $19.62M+7.8% | $18.2M+35.0% | $13.47M+227% | $4.12M-59.0% | ||
| $267K-95.8% | $6.4M— | $0— | —— | —— | ||
| $1.21M-9.7% | $1.34M-8.8% | $1.47M-9.7% | $1.63M-9.6% | $1.8M-10.9% | ||
| $1.21M-9.7% | $1.34M-8.8% | $1.47M-9.7% | $1.63M-9.6% | $1.8M-10.9% | ||
| $221.17M-14.7% | $259.14M-18.8% | $319.17M-7.9% | $346.6M-3.2% | $358.2M-14.5% | ||
| $1.21M-9.7% | $1.34M-8.8% | $1.47M-9.7% | $1.63M-9.6% | $1.8M-10.9% | ||
| $1K-50.0% | $2K0.0% | $2K-66.7% | $6K-14.3% | $7K-22.2% | ||
| —— | —— | —— | —— | —— | ||
| $74.84M-27.4% | $103.06M+33.7% | $77.11M+8.5% | $71.07M+26.9% | $55.98M-6.8% | ||
| $350.49M-0.3% | $351.52M+7.4% | $327.4M-1.1% | $330.91M-1.6% | $336.23M-49.9% | ||
| $11K-97.6% | $452K-13.9% | $525K+84.2% | $285K-45.9% | $527K+223% | ||
| $1.59B+1.3% | $1.57B+1.1% | $1.55B+1.2% | $1.53B+1.0% | $1.52B+0.8% | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $907K-13.7% | $1.05M-11.7% | $1.19M-10.2% | $1.33M-8.8% | $1.45M-7.9% | ||
| $267K-95.8% | $6.4M— | $0— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $343.97M0.0% | $343.91M+7.1% | $320.99M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Syndax Pharmaceuticals's total assets?
- Syndax Pharmaceuticals (SNDX) holds $472.7M in total assets, down 26.2% year over year.
- How much debt does Syndax Pharmaceuticals have?
- Syndax Pharmaceuticals carries $350.5M in total debt against $41.6M of shareholders' equity, a debt-to-equity ratio of 8.42.
- How much cash does Syndax Pharmaceuticals have?
- Syndax Pharmaceuticals holds $130.9M in cash and equivalents.
- Can Syndax Pharmaceuticals cover its short-term obligations?
- Its current ratio is 5.47 — current assets exceed current liabilities.
- Where does Syndax Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
